US2009239295A1PendingUtilityA1

Dedifferentiated, Programmable Stem Cells of Monocytic Origin, and Their Production and Use

64
Assignee: KREMER BERND KARL FRIEDRICHPriority: Mar 28, 2002Filed: May 28, 2009Published: Sep 24, 2009
Est. expiryMar 28, 2022(expired)· nominal 20-yr term from priority
Inventors:Bernd KremerFred FandrichMaren Née Schulze Ruhnke
A61P 9/02A61P 5/00A61P 9/10A61P 43/00A61P 25/00C12N 2510/00C12N 2501/117C12N 2501/33A61K 2035/124A61P 17/02C12N 5/0629C12N 5/0619C12N 2501/385C12N 2501/10C12N 2501/119A61P 11/00C12N 2501/20A61K 35/15C12N 5/0607C12N 5/0647C12N 2501/11C12N 2501/22C12N 2500/30C12N 5/067C12N 2501/23C12N 5/0645C12N 2501/39C12N 5/0618C12N 2502/14A61L 27/3834A61P 1/16A61P 13/12C12N 2501/235C12N 5/0653A61L 27/3895A61L 27/3886C12N 2506/11A61P 1/18A61L 27/3804C12N 2500/44C12N 5/0622C12N 2501/12C12N 2506/03A61P 17/00C12N 5/0676C12N 5/069A61K 35/12
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the production of adult dedifferentiated, programmable stem cells from human monocytes by cultivation of monocytes in a culture medium which contains M-CSF and IL-3. The invention further relates to pharmaceutical preparations, which contain the dedifferentiated, programmable stem cells and the use of these stem cells for the production of target cells and target tissue.

Claims

exact text as granted — not AI-modified
1 - 34 . (canceled) 
   
   
       35 . A cell containing fat vacuoles, wherein said cell expresses a membrane-associated CD14 antigen. 
   
   
       36 . The cell of  claim 35 , wherein said cell is stained by Sudan red. 
   
   
       37 . The cell of  claim 35 , wherein said cell expresses a mRNA sequence selected from the group consisting of peroxisome proliferative activated receptor gamma and leptin. 
   
   
       38 . The cell of  claim 35 , wherein said cell is isolated in a medium. 
   
   
       39 . The cell of  claim 38 , wherein said medium comprises fat cell conditioned medium (FCCM). 
   
   
       40 . The cell of  claim 38 , wherein said medium comprises IL-3. 
   
   
       41 . The cell of  claim 38 , wherein said medium comprises 2-mercaptoethanol. 
   
   
       42 . The cell of  claim 35 , further comprising a medium. 
   
   
       43 . The cell of  claim 42 , wherein said medium comprises FCCM. 
   
   
       44 . The cell of  claim 42 , wherein said medium comprises IL-3. 
   
   
       45 . The cell of  claim 42 , wherein said medium comprises 2-mercaptoethanol. 
   
   
       46 . An adipocyte derived from a dedifferentiated, programmable cell derived from a monocyte that expresses a CD14 antigen and a CD90 antigen. 
   
   
       47 . The adipocyte of  claim 46 , wherein said adipocyte comprises fat vacuoles. 
   
   
       48 . The adipocyte of  claim 46 , wherein said adipocyte is stained by Sudan red. 
   
   
       49 . The adipocyte of  claim 46 , wherein said adipocyte expresses a mRNA sequence typical of fat cell metabolism selected from the group consisting of peroxisome proliferative activated receptor gamma and leptin. 
   
   
       50 . The adipocyte of  claim 46 , wherein said adipocyte is isolated in a medium. 
   
   
       51 . The adipocyte of  claim 50 , wherein said medium comprises fat cell conditioned medium (FCCM). 
   
   
       52 . The adipocyte of  claim 51 , wherein said medium comprises IL-3. 
   
   
       53 . The adipocyte of  claim 46 , further comprising a medium. 
   
   
       54 . The adipocyte of  claim 53 , wherein the medium further comprises FCCM.

Join the waitlist — get patent alerts

Track US2009239295A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.